Travoprost

Identification

Name
Travoprost
Accession Number
DB00287
Description

Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure Label. It is a synthetic prostaglandin F2alpha analog Label. Having been a well-received therapeutic agent with demonstrated efficacy and safety, travoprost is currently approved by the US FDA as a first-line treatment for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypotension 8. Furthermore, this approval also solidifies the medication as the first and only prostaglandin analog approved by the FDA for first-line treatment of glaucoma patients that does not contain the preservative benzalkonium chloride 8. Moreover, travoprost is also currently approved in the EU for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma 6,7.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 500.5477
Monoisotopic: 500.238573467
Chemical Formula
C26H35F3O6
Synonyms
  • isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
  • Travoprost
  • Travoprostum

Pharmacology

Indication

Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension 9,10,6.

Travoprost is also currently indicated for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma 6.

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Travoprost, an isopropyl ester prodrug, is a synthetic prostaglandin F2 alpha analog that is rapidly hydrolyzed by esterases in the cornea to its biologically active free acid Label. The travoprost free acid is potent and highly selective for the FP prostanoid receptor Label.

Mechanism of action

Travoprost, a prostaglandin F2α analogue, is a highly selective full agonist which has a high affinity for the prostaglandin FP receptor, and facilitates reductions in intraocular pressure by increasing the outflow of aqueous humour via trabecular meshwork and uveoscleral pathways 9,10,6. Reduction of the intraocular pressure in man starts about 2 hours after administration and maximum effect is reached after 12 hours. Significant lowering of intraocular pressure can be maintained for periods exceeding 24 hours with a single dose 9,10,6.

TargetActionsOrganism
AProstaglandin F2-alpha receptor
agonist
Humans
Absorption

Travoprost is systemically absorbed through the cornea 9,10,6. In humans, peak plasma concentrations of travoprost free acid were low (25 pg/mL or less) and occurred within 30 minutes following topical ocular administration of one drop of 0.004% travoprost ophthalmic solution 9,10,6.

Volume of distribution

Given the data currently available, it has been recorded that travoprost free acid is moderately distributed into body tissues with a volume of distribution of 2.6 L/kg in rats 10.

Protein binding

The binding of travoprost free acid to plasma proteins is moderate at 80% and linear over a 10,000-fold concentration range (0.10 - 100 ng/mL) 10.

Metabolism

Travoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to its biologically active free acid 9,10. Systemically, travoprost free acid is rapidly and extensively metabolized in the kidney, liver, and lung to inactive metabolites via beta-oxidation of the α(carboxylic acid) chain to give the 1,2-dinor and 1,2,3,4-tetranor analogs, via oxidation of the 15-hydroxyl moiety, as well as via reduction of the 13,14 double bond 9,10.

Hover over products below to view reaction partners

Route of elimination

Less than 2% of the topical ocular dose of travoprost was excreted in the urine within 4 hours as the travoprost free acid 9,10,6. Moreover, elimination from plasma is rapid, resulting in concentrations below the limit of quantitation (< 10 pg/mL) by one hour 9,10,6.

Furthermore, in rats, 95% of a subcutaneous radiolabeled dose was eliminated within 24 hours 9,10. The major route of elimination was via the bile (61%) with the remainder excreted by the kidneys 9,10.

Half-life

The terminal elimination half-life of travoprost free acid is determined to be approximately 45 minutes, although studies demonstrated half-life values that ranged from 17 to 86 minutes 9,10.

Clearance

Data regarding the clearance of travoprost is not readily available or accessible.

Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

No cases of overdose have been reported for travoprost 6. A topical overdose is not likely to occur or to be associated with toxicity 6. A topical overdose of travoprost may be flushed from the eye(s) with lukewarm water 6. Treatment of a suspected oral ingestion is symptomatic and supportive 6.

Travoprost has harmful pharmacological effects on pregnancy and/or the fetus/new-born child. Travoprost should not be used during pregnancy unless clearly necessary 6. The medication subsequently must not be used in women of childbearing age/potential unless adequate contraceptive measures are in place 6.

It is unknown whether travoprost from the eye drops is excreted in human breast milk. Animal studies have shown excretion of travoprost and metabolites in breast milk 9,10,6. The use of travoprost by breast-feeding mothers is not recommended 6.

There are no data on the effects of TRAVATAN on human fertility 9,10,6. Animal studies showed no effect of travoprost on fertility at doses more than 250 times the maximum recommended human ocular dose 6.

Use in patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use 9,10.

No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients 9,10.

Travoprost has been studied in patients with mild to severe hepatic impairment and in patients with mild to severe renal impairment (creatinine clearance as low as 14 ml/min) [L514. No dosage adjustment is necessary for these patients 6.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololTravoprost may increase the hypotensive activities of Acebutolol.
AceclofenacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Aceclofenac.
AcemetacinThe therapeutic efficacy of Travoprost can be decreased when used in combination with Acemetacin.
Acetylsalicylic acidThe therapeutic efficacy of Travoprost can be decreased when used in combination with Acetylsalicylic acid.
AlclofenacThe therapeutic efficacy of Travoprost can be decreased when used in combination with Alclofenac.
AliskirenTravoprost may increase the hypotensive activities of Aliskiren.
AmbrisentanTravoprost may increase the hypotensive activities of Ambrisentan.
AminophenazoneThe therapeutic efficacy of Travoprost can be decreased when used in combination with Aminophenazone.
AmlodipineTravoprost may increase the hypotensive activities of Amlodipine.
AntipyrineThe therapeutic efficacy of Travoprost can be decreased when used in combination with Antipyrine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

International/Other Brands
Travo-Z
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
IzbaSolution0.03 mg/1mLOphthalmicAlcon, Inc.2014-06-022014-06-02US flag
IzbaSolution0.003 %OphthalmicNovartis2017-02-06Not applicableCanada flag
IzbaSolution / drops30 μg/mlOphthalmicNovartis Europharm Limited2014-02-20Not applicableEU flag
IzbaSolution / drops30 μg/mlOphthalmicNovartis Europharm Limited2014-02-20Not applicableEU flag
TravatanSolution / drops40 μg/mlOphthalmicNovartis Europharm Limited2001-11-27Not applicableEU flag
TravatanSolution / drops40 μg/mlOphthalmicNovartis Europharm Limited2001-11-27Not applicableEU flag
TravatanSolution / drops40 μg/mlOphthalmicNovartis Europharm Limited2001-11-27Not applicableEU flag
TravatanSolution / drops40 μg/mlOphthalmicNovartis Europharm Limited2001-11-27Not applicableEU flag
TravatanSolutionOphthalmicAlcon, Inc.2001-11-132010-11-16Canada flag
TravatanSolution0.04 mg/1mLOphthalmicAlcon, Inc.2001-03-162010-07-01US flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Apo-travoprostSolutionOphthalmicApotex CorporationNot applicableNot applicableCanada flag
Apo-travoprost ZSolutionOphthalmicApotex Corporation2014-08-14Not applicableCanada flag
Mylan-travoprost ZSolutionOphthalmicMylan PharmaceuticalsNot applicableNot applicableCanada flag
PMS-travoprost ZSolutionOphthalmicPharmascience IncNot applicableNot applicableCanada flag
Sandoz TravoprostSolutionOphthalmicSandoz Canada Incorporated2014-08-15Not applicableCanada flag
Teva-travoprost Z Ophthalmic SolutionSolutionOphthalmicTEVA Canada Limited2014-08-182020-06-10Canada flag
TravoprostSolution0.04 mg/1mLOphthalmicApotex Corp.2019-12-18Not applicableUS flag
Travoprost Ophthalmic SolutionSolution / drops0.04 mg/1mLOphthalmicSandoz Inc2019-12-18Not applicableUS flag
Travoprost Ophthalmic Solution 0.004%Solution0.04 mg/1mLOphthalmicPar Pharmaceutical, Inc.2013-04-152019-10-31US flag
Travoprost Ophthalmic Solution USP, 0.004% TravoprostSolution / drops0.04 mg/1mLOphthalmicAlembic Pharmaceuticals Inc.2019-12-20Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Apo-travoprost-timolol PqTravoprost (0.004 %) + Timolol (0.5 %)SolutionOphthalmicApotex CorporationNot applicableNot applicableCanada flag
Apo-travoprost-timop PqTravoprost (0.004 %) + Timolol (0.5 %)SolutionOphthalmicApotex Corporation2018-12-06Not applicableCanada flag
Duotrav PqTravoprost (0.004 %) + Timolol (0.5 %)SolutionOphthalmicNovartis2006-04-11Not applicableCanada flag
Sandoz Travoprost / Timolol PqTravoprost (0.004 %) + Timolol (0.5 %)SolutionOphthalmicSandoz Canada IncorporatedNot applicableNot applicableCanada flag

Categories

ATC Codes
S01EE04 — Travoprost
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Eicosanoids
Direct Parent
Prostaglandins and related compounds
Alternative Parents
Trifluoromethylbenzenes / Phenoxy compounds / Phenol ethers / Fatty acid esters / Alkyl aryl ethers / Cyclopentanols / Cyclic alcohols and derivatives / Carboxylic acid esters / Monocarboxylic acids and derivatives / Organofluorides
show 4 more
Substituents
Alcohol / Alkyl aryl ether / Alkyl fluoride / Alkyl halide / Aromatic homomonocyclic compound / Benzenoid / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Cyclic alcohol
show 16 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
carboxylic ester, prostaglandins Falpha, (trifluoromethyl)benzenes (CHEBI:746859)

Chemical Identifiers

UNII
WJ68R08KX9
CAS number
157283-68-6
InChI Key
MKPLKVHSHYCHOC-AHTXBMBWSA-N
InChI
InChI=1S/C26H35F3O6/c1-17(2)35-25(33)11-6-4-3-5-10-21-22(24(32)15-23(21)31)13-12-19(30)16-34-20-9-7-8-18(14-20)26(27,28)29/h3,5,7-9,12-14,17,19,21-24,30-32H,4,6,10-11,15-16H2,1-2H3/b5-3-,13-12+/t19-,21-,22-,23+,24-/m1/s1
IUPAC Name
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl]cyclopentyl]hept-5-enoate
SMILES
CC(C)OC(=O)CCC\C=C/C[[email protected]]1[[email protected]@H](O)C[[email protected]@H](O)[[email protected]@H]1\C=C\[[email protected]@H](O)COC1=CC=CC(=C1)C(F)(F)F

References

General References
  1. Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.e4. doi: 10.1016/j.ophtha.2007.07.002. [PubMed:18452763]
  2. Costagliola C, dell'Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F: Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother. 2009 Dec;10(17):2859-70. doi: 10.1517/14656560903300129. [PubMed:19929706]
  3. Ferrari G, Scagliotti GV: Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients. Eur J Cancer. 1996 Dec;32A(13):2368-9. [PubMed:9038626]
  4. Toris CB, Gabelt BT, Kaufman PL: Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008 Nov;53 Suppl1:S107-20. doi: 10.1016/j.survophthal.2008.08.010. [PubMed:19038618]
  5. Arranz-Marquez E, Teus MA: Prostanoids for the management of glaucoma. Expert Opin Drug Saf. 2008 Nov;7(6):801-8. doi: 10.1517/14740330802465474 . [PubMed:18983226]
  6. Electronic Medicines Compendium: Travatan (travoprost) Monograph [Link]
  7. Alcon treatment Travatan® receives EU approval for pediatric glaucoma patients: Press Release [Link]
  8. Alcon receives FDA approval for first-line use of Travatan Z: Press Release [Link]
  9. Travatan Z (travoprost) FDA Label [File]
  10. Travoprost Canadian Product Information [File]
Human Metabolome Database
HMDB0014432
KEGG Drug
D01964
PubChem Compound
5282226
PubChem Substance
46507637
ChemSpider
4445407
RxNav
283809
ChEBI
746859
ChEMBL
CHEMBL1200799
ZINC
ZINC000004474682
Therapeutic Targets Database
DAP000274
PharmGKB
PA164781371
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Travoprost
AHFS Codes
  • 52:40.28 — Prostaglandin Analogs
FDA label
Download (36.8 KB)
MSDS
Download (72.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedNot AvailableGlaucoma2
4CompletedDiagnosticGlaucoma / Ocular Hypertension1
4CompletedSupportive CareDry Eye Syndrome (DES)1
4CompletedTreatmentAngle-Closure Glaucoma1
4CompletedTreatmentAnterior Uveitis (AU) / Cystoid Macular Edema1
4CompletedTreatmentApplication Site Pigmentation Changes / Glaucoma1
4CompletedTreatmentGlaucoma12
4CompletedTreatmentGlaucoma, Primary Open Angle (POAG) / Ocular Hypertension / Pigment Dispersion Glaucoma1
4CompletedTreatmentGlaucoma / Ocular Hypertension9
4CompletedTreatmentGlaucoma / Ocular Hypertension / Open-angle Glaucoma (OAG)1

Pharmacoeconomics

Manufacturers
  • Alcon inc
Packagers
  • Alcon Laboratories
  • Liberty Carton Co.
  • Physicians Total Care Inc.
Dosage Forms
FormRouteStrength
Solution / dropsOphthalmic40 MCG/ML
SolutionConjunctival; Ophthalmic5 mg
Solution / dropsOphthalmic40 MICROGRAMMI/ML
Solution / dropsOphthalmic0.004 %
Solution / dropsOphthalmic500 mg/100mL
Solution / drops; suspension / dropsOphthalmic0.04 mg/mL
SolutionOphthalmic40 μg/ml
SolutionConjunctival; Ophthalmic0.04 mg
Solution / dropsOphthalmic40 Mikrogramm/ml
SolutionConjunctival; Ophthalmic40 cg
SolutionOphthalmic0.003 %
SolutionOphthalmic0.03 mg/1mL
Solution / dropsOphthalmic3 mg/100mL
Solution / dropsOphthalmic30 MCG/ML
Solution / dropsOphthalmic30 μg/ml
SolutionOphthalmic
SolutionOphthalmic
Solution / dropsOphthalmic40 mcg
SolutionOphthalmic0.04 mg/1mL
Solution / dropsOphthalmic4 mg/100mL
Solution / dropsOphthalmic40 μg/ml
SolutionOphthalmic0.004 %
Solution / dropsOphthalmic
Solution / drops; suspension / dropsOphthalmic
Solution / drops; suspension / dropsOphthalmic40 UG
SolutionOphthalmic0.04 mg
Solution / drops; suspension / dropsOphthalmic40 UG/ML
Solution / drops; suspension / dropsOphthalmic40 mcg/mL
Solution / dropsOphthalmic0.04 mg/1mL
Prices
Unit descriptionCostUnit
Travatan 0.004% Solution 5ml Bottle190.82USD bottle
Travatan Z 0.004% Solution 5ml Bottle190.82USD bottle
Travatan 0.004% Solution 2.5ml Bottle95.41USD bottle
Travatan Z 0.004% Solution 2.5ml Bottle95.41USD bottle
Travatan 0.004% eye drop45.87USD ml
Travatan z 0.004% eye drop36.7USD ml
Travatan 0.004 % Solution12.18USD ml
Travatan Z 0.004 % Solution12.18USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5631287No1997-05-202014-12-22US flag
US6503497No2003-01-072012-05-06US flag
CA2181172No2003-04-292015-12-19Canada flag
CA2129287No2002-05-142014-08-02Canada flag
US8268299No2012-09-182029-10-13US flag
US8323630No2012-12-042027-09-20US flag
US8388941No2013-03-052027-09-20US flag
US9144561No2015-09-292029-03-13US flag
US8722735No2014-05-132029-10-10US flag
US8178582No2012-05-152029-10-10US flag
US8754123No2014-06-172029-05-19US flag
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Liquid
Experimental Properties
PropertyValueSource
water solubility>16 mg/ml at 25.0°CNot Available
logP4.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00759 mg/mLALOGPS
logP4.02ALOGPS
logP3.84ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)13.95ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area96.22 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity127.86 m3·mol-1ChemAxon
Polarizability51.61 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9857
Blood Brain Barrier+0.887
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.5907
P-glycoprotein inhibitor INon-inhibitor0.8237
P-glycoprotein inhibitor IINon-inhibitor0.6435
Renal organic cation transporterNon-inhibitor0.8856
CYP450 2C9 substrateNon-substrate0.8327
CYP450 2D6 substrateNon-substrate0.8383
CYP450 3A4 substrateSubstrate0.652
CYP450 1A2 substrateNon-inhibitor0.728
CYP450 2C9 inhibitorNon-inhibitor0.7607
CYP450 2D6 inhibitorNon-inhibitor0.9125
CYP450 2C19 inhibitorNon-inhibitor0.6844
CYP450 3A4 inhibitorNon-inhibitor0.8546
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7657
Ames testNon AMES toxic0.7427
CarcinogenicityNon-carcinogens0.9088
BiodegradationNot ready biodegradable0.9726
Rat acute toxicity3.5280 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9744
hERG inhibition (predictor II)Non-inhibitor0.6722
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Agonist
General Function
Prostaglandin f receptor activity
Specific Function
Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis...
Gene Name
PTGFR
Uniprot ID
P43088
Uniprot Name
Prostaglandin F2-alpha receptor
Molecular Weight
40054.1 Da
References
  1. Ota T, Aihara M, Narumiya S, Araie M: The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4159-63. [PubMed:16249494]
  2. Thieme H, Schimmat C, Munzer G, Boxberger M, Fromm M, Pfeiffer N, Rosenthal R: Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci. 2006 Mar;47(3):938-45. [PubMed:16505027]
  3. Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.e4. doi: 10.1016/j.ophtha.2007.07.002. [PubMed:18452763]
  4. Neacsu AM: [Receptors involved in the mechanism of action of topical prostaglandines]. Oftalmologia. 2009;53(2):3-7. [PubMed:19697832]
  5. Costagliola C, dell'Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F: Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother. 2009 Dec;10(17):2859-70. doi: 10.1517/14656560903300129. [PubMed:19929706]
  6. Ferrari G, Scagliotti GV: Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients. Eur J Cancer. 1996 Dec;32A(13):2368-9. [PubMed:9038626]
  7. Toris CB, Gabelt BT, Kaufman PL: Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008 Nov;53 Suppl1:S107-20. doi: 10.1016/j.survophthal.2008.08.010. [PubMed:19038618]
  8. Arranz-Marquez E, Teus MA: Prostanoids for the management of glaucoma. Expert Opin Drug Saf. 2008 Nov;7(6):801-8. doi: 10.1517/14740330802465474 . [PubMed:18983226]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on October 23, 2020 21:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates